Citations

Clear

7552 citation(s) found for "Ho, Matthew".

Thermal Ablation of Bone Metastases
Kurup, A. Nicholas , Callstrom, Matthew R. , Moynagh, Michael R., Kurup, Anil N

Mayo Clinic

Seminars in Interventional Radiology | November 5, 2018 | Volume: 35 | Issue: 04 | Pages: 299-308

10.1055/s-0038-1673422 | PMID 30402013 Get It

AbstractImage-guided, minimally invasive, percutaneous thermal ablation of bone metastases has unique advantages compared with surgery or radiation therapy. Thermal ablation of osseous metastases may result in significant pain palliation, prevention of skeletal-related events, and durable local tumor control. This article will describe current thermal ablation techniques utilized to treat bone metastases, summarize contemporary evidence supporting such thermal ablation treatments, and outline an approach to percutaneous ablative treatment.
A Cross-Sectional Survey of the North American Skull Base Society Part 3: The State of Lateral Skull Base Surgery Training in North America
Patel, Neil , Tombers, Nicole M. , Link, Michael J. , Carlson, Matthew L. , Gompel, Jamie J. Van

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | November 5, 2018 | Volume: 80 | Issue: 04 | Pages: 399-415

10.1055/s-0038-1675557 | PMID 31316886 Get It

Introduction Optimal management of vestibular schwannoma (VS) demands involvement of an experienced multidisciplinary team. As the number of training programs in neurotology and skull base neurosurgery continues to rise, ensuring that trainees are capable of evidence-based decision-making and treatment, whether microsurgical or radiosurgical, is of paramount importance. The purpose of this study is to characterize the landscape of neurotologic and neurosurgical fellowship training programs in North America, with special reference to VS management. Methods A 64-item web-based survey assessing VS practice trends was devised by members of the North American Skull Base Society (NASBS) Research Task Force and distributed electronically to NASBS membership via SurveyMonkey as a cross-sectional study. Participation was entirely voluntary and there was no remuneration for survey completion. The survey link was active from November 29 to December 14, 2016. Results Of 719 members of the NASBS who were emailed a survey link, a total of 57 were returned (8%) completed surveys. Of all respondents, 51 (89%) claimed to have formal training in skull base neurosurgery or neurotology. Thirty-three respondents (65%) were skull base neurosurgeons while the remainder were neurotologists (n = 18; 35%). Institutions with fellowship programs tended to have a higher surgical, radiosurgical, and overall case volume than those with a residency program alone. However, 20% of respondents at institutions with fellowship programs reported evaluating less than 50 new diagnoses of VS per year and 12% reported a surgical case volume of less than 10 cases per year. Conclusion As the number of skull base training programs expands, it is our duty to ensure that trainees gain sufficient experience to enter independent practice with the ability to exercise informed decision-making and safely perform VS surgery and radiosurgery. In the current training climate, implementing multidisciplinary care models, formalized training requirements, and emerging surgical simulators will support the development of minimum proficiencies in VS care.
GENE-11. SMALL TERMINAL ALTERATIONS AND ALTERNATIVE LENGTHENING OF TELOMERES ARE A FEATURE OF IDH-MUTANT, 1p/19q NON-CODELETED GLIOMAS
Yamada, Seiji , Jacobs, Joshua , Decker, Paul A. , Kosel, Matt, Caron, Alissa, Halder, Chandralekha, Ruiz, Vanessa , Kipp, Benjamin R. , Voss, Jesse S. , Vaubel, Rachel, Jenkins, Robert B. , Brown, Desmond , Praska, Corinne , Kollmeyer, Thomas M. , Decker, Paul A. , Kosel, Matthew , Giannini, Caterina

Mayo Clinic

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi105-vi105

10.1093/neuonc/noy148.438 Get It

GENE-29. DLL3 AND ETV1 ARE INACTIVATED/METHYLATED IN CIC WILD-TYPE, IDH-MUTATED, 1p/19q-CODELETED GLIOMA
Kosel, Matthew , Decker, Paul A. , Caron, Alissa, Sarkar, Gobinda , Halder, Chandralekha, Tian, Shulan , Eckel‐Passow, Jeanette E. , Jenkins, Robert B. , Lachance, Daniel Honore , Decker, Paul A. , Kollmeyer, Thomas M. , Drucker, Kristen , Knight, Andrew, Abyzov, Alexej , Burns, Terry C. , Giannini, Caterina

Mayo Clinic

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi109-vi109

10.1093/neuonc/noy148.455 Get It

TMOD-18. THE PATIENT DERIVED XENOGRAFT NATIONAL RESOURCE: A COMPREHENSIVE COLLECTION OF HIGH-GRADE GLIOMA MODELS FOR PRE-CLINICAL AND TRANSLATIONAL STUDIES
Tian, Shulan , Peng, Sen, Carlson, Brett L. , Kitange, Gaspar J. , Evers, Lisa, Decker, Paul A. , Kosel, Matthew , Klee, Eric W. , James, C. David , Eckel‐Passow, Jeanette E. , Verhaak, Roel G.W. , Jenkins, Robert B. , Vaubel, Rachael A. , Remonde, Dioval , Schroeder, Mark A. , Kollmeyer, Thomas M. , Mladek, Ann C. , Daniel, J. , Decker, Paul A. , Berens, Michael E. , Califano, Andrea , Lachance, Daniel Honore , Sulman, Erik P. , Tran, Nhan L. , Giannini, Caterina , Parney, Ian F. , Sarkaria, Jann N.

Mayo Clinic

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi272-vi272

10.1093/neuonc/noy148.1130 Get It

Outcome for pediatric acute promyelocytic leukemia patients at Children's Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (Alliance)
Kutny, Matthew A. , Geyer, Susan, Laumann, Kristina, Gregory, John , Powell, Bayard L., Feusner, James H., Laumann, Kristina M, Willman, Cheryl L. , Stock, Wendy , Larson, Richard A.

Mayo Clinic

Pediatric Blood & Cancer | November 5, 2018 | Volume: 66 | Issue: 3 | Pages: No page available

10.1002/pbc.27542 | PMID 30393935 Get It

AbstractBackgroundAcute promyelocytic leukemia (APL) is a unique leukemia subtype requiring specialized treatment including all‐trans retinoic acid (ATRA). A prior report demonstrated worse outcome among young children <5 years old compared with older children.MethodsWe evaluated outcomes for pediatric patients (<18 years old; N = 83) with APL treated on North American intergroup study CALGB 9710 at Children's Oncology Group sites. Induction and consolidation included ATRA, cytarabine, and anthracyclines. Patients ≥15 years old were randomized to addition of arsenic trioxide (ATO) consolidation. All patients were randomized to ATRA maintenance with versus without oral chemotherapy.ResultsThe estimated 5‐year overall survival (OS) rate was 82%, and the event‐free survival (EFS) rate was 54%. Seven patients (8.4%) died during induction due to coagulopathy. Maintenance randomization demonstrated that addition of oral chemotherapy to ATRA significantly reduced relapse rate, but difference in EFS did not reach statistical significance (P = 0.12; 5‐year rates [95% CI]: 41% [17%–64%] ATRA only vs 72% [56%–88%] ATRA plus chemotherapy). There was no difference (P = 0.93) in EFS for age <5 years versus 5–12.99 years versus 13–17.99 years (5‐year rates: 56%, 47%, and 45%, respectively). Among adolescents 15–17.99 years old in the ATO randomization, there was a significantly lower relapse risk at 5 years for those receiving ATO (0% ATO vs 44% no ATO; P = 0.02).ConclusionOur data demonstrate that intensified ATRA, cytarabine, and anthracycline chemotherapy is effective for pediatric APL including very young patients, but early deaths and relapses remain barriers to cure. Further improvements are likely with incorporation of ATO into pediatric APL regimens.
Higher intraoperative plasma transfusion volumes are associated with inferior perioperative outcomes
Frank, Ryan D. , Weister, Timothy J. , Stubbs, James R. , Kor, Daryl J. , Smith, Mark M. , Warner, Matthew A.

Mayo Clinic

Transfusion | November 1, 2018 | Volume: 59 | Issue: 1 | Pages: 112-124

10.1111/trf.14988 | PMID 30383908 Get It

BACKGROUNDIntraoperative plasma transfusion is common, yet little is known regarding its effects on perioperative coagulation tests or clinical outcomes.STUDY DESIGN AND METHODSThis is a retrospective cohort study of adults receiving intraoperative plasma transfusion at a single center from 2011 to 2015. Relationships between plasma transfusion volume, changes in coagulation test values, and clinical outcomes, including a primary outcome of early postoperative red blood cell (RBC) transfusion, were assessed with multivariable regression analyses. Secondary outcomes included hospital mortality, intensive care unit (ICU)‐ and hospital‐free days, intraoperative RBC transfusions, and estimated blood loss.RESULTSA total of 3393 unique patients were included, with median (IQR) transfusion of 2 (2‐4) units. In multivariable analyses, higher plasma volumes were associated with worse outcomes, with each 1 mL/kg increase associated with increased odds for postoperative (1.02 [1.01‐1.03], p < 0.001) and intraoperative RBCs (1.17 [1.16‐1.19], p < 0.001) and fewer ICU‐ and hospital‐free days (mean difference [95% CI], –0.08 [−0.12 to −0.05], p < 0.001; and −0.09 [−0.13 to −0.06], p < 0.001, respectively). Greater decreases in international normalized ratio (INR) following plasma transfusion were associated with decreased odds of postoperative RBCs (0.35 [0.25‐0.47], p < 0.001), decreased mortality (0.50 [0.31‐0.83], p = 0.007), and increased mean ICU‐ (1.31 [0.41‐2.21], p = 0.004) and hospital‐free days (1.15 [0.19‐2.10], p = 0.018).CONCLUSIONIn patients receiving intraoperative plasma transfusion, higher transfusion volumes were associated with inferior clinical outcomes; however, greater improvements in INR were associated with improved outcomes. Future prospective studies are necessary to better define these relationships and to explore plasma transfusion triggers beyond the limitations of INR.
In Response
Kor, Daryl J. , Warner, Matthew A.

Mayo Clinic

Anesthesia & Analgesia | October 30, 2018 | Volume: 128 | Issue: 1 | Pages: e14-e15

10.1213/ane.0000000000003900 | PMID 30379680 Get It

The von Willebrand factor Tyr2561 allele is a gain-of-function variant and a risk factor for early myocardial infarction
Schneppenheim, Reinhard , Hellermann, Natalie, Brehm, Maria A. , Klemm, Ulrike, Obser, Tobias, Huck, Volker , Schneider, Stefan W. , Denis, Cécile V. , Tischer, Alexander , Auton, Matthew , Xu, Emma-Ruoqi , Wilmanns, Matthias , Zotz, Rainer B., Xu, Emma-Ruoqi , Wilmanns, Matthias , Auton, Matthew , Tischer, Alexander , März, Winfried

Mayo Clinic

Blood | October 26, 2018 | Volume: 133 | Issue: 4 | Pages: 356-365

10.1182/blood-2018-04-843425 | PMID 30366922 Get It

Abstract The frequent von Willebrand factor (VWF) variant p.Phe2561Tyr is located within the C4 domain, which also harbors the platelet GPIIb/IIIa-binding RGD sequence. To investigate its potential effect on hemostasis, we genotyped 865 patients with coronary artery disease (CAD), 915 with myocardial infarction (MI), and 417 control patients (Ludwigshafen Risk and Cardiovascular Health Study) and performed functional studies of this variant. A univariate analysis of male and female carriers of the Tyr2561 allele aged 55 years or younger revealed an elevated risk for repeated MI (odds ratio, 2.53; 95% confidence interval [CI], 1.07-5.98). The odds ratio was even higher in females aged 55 years or younger, at a value of 5.93 (95% CI, 1.12-31.24). Cone and plate aggregometry showed that compared with Phe2561, Tyr2561 was associated with increased platelet aggregate size both in probands’ blood and with the recombinant variants. Microfluidic assays revealed that the critical shear rate for inducing aggregate formation was decreased to 50% by Tyr2561 compared with Phe2561. Differences in C-domain circular dichroism spectra resulting from Tyr2561 suggest an increased shear sensitivity of VWF as a result of altered association of the C domains that disrupts the normal dimer interface. In summary, our data emphasize the functional effect of the VWF C4 domain for VWF-mediated platelet aggregation in a shear-dependent manner and provide the first evidence that a functional variant of VWF plays a role in arterial thromboembolism.